Position in GRFS
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$1,315
+$839 QoQ
Shares Held
164
+221.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 79%
Shared 0%
None 21%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FINANCIAL CONSULATE, INC holds $4,839,565 across 15 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,232 | $1,477,697 | |
| 2 | MRK |
Merck & Co., Inc.
|
7,599 | $976,471 | |
| 3 | JNJ |
Johnson & Johnson
|
3,667 | $931,307 | |
| 4 | ABBV |
AbbVie Inc.
|
3,167 | $796,943 | |
| 5 | AZN |
Astrazeneca PLC
|
870 | $164,969 | |
| 6 | AMGN |
Amgen Inc
|
445 | $161,143 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
1,572 | $90,578 | |
| 8 | NVS |
Novartis AG
|
515 | $80,710 |
All Filings in GRFS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,315 | 164 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $476 | 51 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $507 | 51 | Shares | Sole | 2025-10-21 | |
| No filing history on record for this holder in this stock. | ||||||